# OnCo record alcestobart (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/alcestobart/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "alcestobart" ;
  schema:name "Alcestobart"@en ;
  schema:alternateName "LBL-007"@en ;
  schema:description "Alcestobart is an experimental monoclonal antibody from Nanjing Leads Biolabs, in phase 2 trials for nasopharyngeal carcinoma and melanoma."@en ;
  schema:url <https://onco.cc/drugs/alcestobart/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://www.leadsbiolabs.com/_nuxt/C0xAGIJr.js>, <https://clinicaltrials.gov/api/v2/studies/NCT05609370>, <https://clinicaltrials.gov/search?intr=LBL-007> ;
  onco:status "phase-2" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:modality "Monoclonal antibody (fully human IgG4)" ;
  onco:cancers <https://onco.cc/cancers/melanoma/> ;
  onco:targets <https://onco.cc/targets/lag3/> ;
  onco:companies <https://onco.cc/companies/nanjing-leads-biolabs/> ;
  onco:trials <https://onco.cc/trials/nct05516914/>, <https://onco.cc/trials/nct05102006/>, <https://onco.cc/trials/nct04640545/>, <https://onco.cc/trials/nct05609370/>, <https://onco.cc/trials/nct03744468/>, <https://onco.cc/trials/nct05635708/>, <https://onco.cc/trials/nct05909904/>, <https://onco.cc/trials/nct05577702/>, <https://onco.cc/trials/nct06010303/> .